CollPlant Biotechnologies Ltd. develops regenerative and aesthetic medicine technologies based on plant-derived recombinant human collagen, or rhCollagen. News about CLGN centers on its BioInk and 3D bioprinting portfolio, including Collink.3D and BioFlex, as well as medical aesthetics programs such as photocurable dermal filler technology and tissue-regeneration applications.
Company updates also cover operating and financial results, distribution expansion for rhCollagen and BioInk products, Vergenix STR commercialization, intellectual-property activity, collaboration developments, capital actions and Nasdaq listing-compliance matters.
CollPlant Biotechnologies (Nasdaq: CLGN) has signed definitive agreements for a private placement expected to raise approximately $3.7 million in gross proceeds.
The offering comprises 989,301 ordinary shares or equivalents and warrants to purchase up to 1,483,952 ordinary shares. The combined price is $3.74 per share and accompanying warrants, or $3.7399 per equivalent and accompanying warrants. Warrants are immediately exercisable upon issuance at $3.74 per share. Existing investors comprise most of the placement. CollPlant expects closing on or about October 14, 2026, subject to customary closing conditions, and intends to use net proceeds primarily to accelerate subsidiary LightSolver's laser-based computing research and development. Gross proceeds exclude placement-agent fees and related expenses.
CollPlant Biotechnologies (CLGN) announced that its subsidiary LightSolver has filed a U.S. provisional patent application for its laser-based computing platform.
The application covers a method for configuring a programmable analog processor to solve physical and engineering problems. LightSolver said the invention broadens the platform's potential simulation capabilities by incorporating boundary conditions and other problem parameters directly into computation. It addresses partial differential equations, mathematical equations describing phenomena such as heat transfer, diffusion, electrostatics and fluid flow, including complex geometries and boundary conditions.
CollPlant Biotechnologies (CLGN) reported second-quarter 2026 revenue of $108,000 and a narrower net loss, alongside its completed acquisition of LightSolver. Revenue fell from $179,000 a year earlier. Net loss narrowed to $2.726 million, or $1.89 per share, from $3.347 million, or $2.83 per share. Operating expenses fell to $2.177 million from $3.171 million, while gross loss widened to $456,000 from $7,000.
First-half revenue fell to $181,000 from $2.234 million, and net loss widened to $5.823 million from $4.799 million. June 30 cash was $2.559 million; first-half operating cash use was $5.382 million. After June 30, CollPlant received $1.94 million in remaining gross private-placement proceeds and approximately $5.2 million from warrant exercises. The September acquisition adds laser-based photonic computing to its regenerative medicine business; LightSolver operations are excluded from the reported periods.
CollPlant (CLGN) announced on September 24, 2026, that subsidiary LightSolver and HLRS published joint research on photonic computing for supercomputers.
Researchers used an emulator of LightSolver's Laser Processing Unit to benchmark projected performance against established iterative algorithms running on a GPU. For the large-scale sparse linear-equation problems evaluated, projected time-to-solution acceleration ranged from approximately 40× to more than 80,000×, depending on the algorithm and problem. The figures are emulator-based projections, not reported measurements on LPU hardware. The peer-reviewed paper was published in the proceedings of the 23rd ACM International Conference on Computing Frontiers.
CollPlant Biotechnologies (CLGN) has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share.
Nasdaq confirmed that for the ten consecutive business days from September 4–18, 2026, the closing bid price of CollPlant’s ordinary shares was at or above $1.00, curing the deficiency first flagged on March 23, 2026. Nasdaq considers the listing compliance matter closed. This update follows the recent completion of the LightSolver acquisition, which CollPlant describes as expanding its activities into high-performance computing and photonics alongside its existing rhCollagen-based regenerative medicine business.
CollPlant (CLGN)/b) will host an investor webinar featuring its subsidiary LightSolver on September 17, 2026, at 8:30 a.m. Eastern Time.LightSolver management will introduce the company and its pure photonic computing technology, including its full-stack Laser Processing Unit (LPU) architecture, targeted computational challenges and applications, current validation and collaboration programs, and its roadmap toward commercial deployment. LightSolver became a subsidiary of CollPlant following completion of an acquisition announced on September 3, 2026, which expands CollPlant’s activities into advanced photonic computing alongside its existing regenerative medicine and 3D bioprinting businesses.
CollPlant Biotechnologies (CLGN) appointed Dr. Ruti Ben Shlomi, CEO and Co‑Founder of LightSolver, to its Board of Directors, effective immediately following the completion of CollPlant's acquisition of LightSolver announced on September 3, 2026.
LightSolver develops a proprietary Laser Processing Unit (LPU), an all‑optical, energy‑efficient photonic computing platform designed to accelerate computationally intensive workloads in scientific simulation, engineering, optimization and Physical AI. CollPlant states that Dr. Ben Shlomi's deep expertise in photonic computing and entrepreneurship will support the commercialization of this newly acquired technology.
With the LightSolver acquisition, CollPlant expands from regenerative medicine into advanced high‑performance computing, aiming to address demanding workloads in aerospace, defense and Physical AI while continuing its collagen-based 3D bioprinting, tissue repair and medical aesthetics activities.
CollPlant Biotechnologies (CLGN) completed its previously announced acquisition of Israeli deep-tech company LightSolver, formally entering the high-performance computing and photonics sectors.
LightSolver develops the Laser Processing Unit (LPU), a proprietary all‑optical, laser-based computing architecture designed to accelerate highly computational workloads such as scientific and engineering simulations, partial differential equations, large-scale linear systems and optimization. These capabilities target applications across aerospace, defense, energy, advanced engineering, financial services and Physical AI.
The transaction used an equity-centric structure. At closing, CollPlant issued upfront ordinary shares, pre-funded warrants and made a $5 million investment in LightSolver, with additional milestone-based warrants to become exercisable if specified technological and commercial objectives are achieved. CollPlant states that photonic computing activities will run alongside its existing regenerative medicine operations, which are based on its recombinant human collagen and 3D bioprinting platforms.
CollPlant (Nasdaq: CLGN) announced that its board has approved a one-for-ten reverse share split of its ordinary shares, following shareholder approval at the August 18, 2026 extraordinary general meeting. The split will take effect at the opening of trading on September 4, 2026, when CLGN will begin trading on a split-adjusted basis.
According to CollPlant, the reverse split is part of its strategic plan to regain compliance with Nasdaq’s minimum bid price requirement. Fractional shares will be rounded to the nearest whole share, and all outstanding options and warrants will be proportionately adjusted. The new CUSIP will be M2R51X124.
CollPlant (Nasdaq: CLGN) signed a definitive agreement to acquire Israeli deep-tech company LightSolver, which is developing a pure photonic computing architecture centered on its Laser Processing Unit™ (LPU™). The LPU is designed as an all-optical computing layer alongside CPUs and GPUs, targeting high-intensity workloads in simulation, optimization and Physical AI, with commercial availability targeted for 2028.
According to CollPlant, consideration includes 3,734,476 new ordinary shares (19.7% of pre-deal share capital), pre-funded warrants for 6,134,363 shares, and milestone-based warrants for 224,078,345 shares, plus rollover options for 2,261,966 shares, largely exercisable upon LightSolver achieving specified technological and commercial milestones and subject to shareholder approval above an equity blocker.